论文部分内容阅读
【目的】观察慢性重症肝炎患者血清TNF-α和IL-8水平及其在前列腺素E1(PGE1)治疗前后的变化。【方法】设立正常对照组、一般治疗组和前列腺素E1治疗组,采用酶联免疫吸附试验(ELISA)检测各组血清IL-8和TNF-α水平。【结果】慢性重症肝炎患者血清IL-8、TNF-α水平较对照组明显升高(P<0.05~0.01),PGE1治疗4周后,其血清IL-8水平明显下降(P<0.05),PGE1治疗8周后,血清TNF-α和IL-8水平均明显下降(P<0.01)。【结论】慢性重症肝炎患者血清IL-8和TNF-α水平与肝脏损伤程度密切相关,是判定患者预后和疗效的重要指标,PGE1可以减轻肝脏的炎症反应,改善肝功能。
【Objective】 To observe the changes of serum TNF-α and IL-8 levels in patients with chronic severe hepatitis before and after prostaglandin E1 (PGE1) treatment. 【Methods】 The normal control group, general treatment group and prostaglandin E1 treatment group were established. Serum levels of IL-8 and TNF-α were detected by enzyme linked immunosorbent assay (ELISA). 【Results】 Serum levels of IL-8 and TNF-α in patients with chronic severe hepatitis were significantly higher than those in control group (P <0.05-0.01). After 4 weeks of treatment, serum IL-8 level was significantly decreased (P <0.05) PGE1 treatment for 8 weeks, serum TNF-α and IL-8 levels were significantly decreased (P <0.01). 【Conclusion】 Serum levels of IL-8 and TNF-α in patients with chronic severe hepatitis are closely related to the degree of liver injury. It is an important index for judging the prognosis and efficacy of patients. PGE1 can reduce the inflammatory reaction and improve the liver function.